Study population and tumor characteristics
| Patient # | Age | Sex | Tumor classification | PDL1 Status | ALK | EGFR |
| 1 | 87 | F | NSCLC-adeno | P (HI, >50%) | N | N |
| 2 | 74 | F | NSCLC-squamous | P (LOW, 1%–49%) | N | N |
| 3 | 62 | F | NSCLC-squamous | P (LOW, 1%–49%) | NA | NA |
| 4 | 65 | M | NSCLC-adeno | N (<1%) | NA | N |
| 5 | 53 | M | NSCLC-adeno | P (LOW, 1%–49%) | N | N |
| 6 | 68 | M | Mixed SCLC/NSCLC | NA | NA | NA |
| 7 | 60 | M | NSCLC-squamous | N (<1%) | N | N |
| 8 | 81 | F | NSCLC-adeno | P (HI, >50%) | N | N |
| 9 | 73 | F | NSCLC-squamous | P (HI, >50%) | N | N |
| 10 | 63 | F | NSCLC-adeno | P (LOW, 1%–49%) | N | P |
| 11 | 78 | M | NSCLC-adeno | P (HI, >50%) | N | N |
| 12 | 79 | F | NSCLC-adeno | N (<1%) | N | N |
| 13 | 76 | F | NSCLC-large cell neuroendocrine | NA | NA | NA |
| 14 | 64 | M | SCLC | NA | NA | NA |
| 15 | 76 | F | NSCLC-adeno | P (HI, >50%) | N | N |
| 16 | 63 | M | NSCLC-squamous | P (LOW, 1%–49%) | NA | NA |
High-positive (HI); TPS ≥50%. Low-positive (LOW); TPS ≥1% and≤49%. Negative; TPS <1%.
adeno, adenocarcinoma; ALK, Anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; N, negative status; NA, not available; NSCLC, non-small cell lung cancer; P, positive status; SCLC, small-cell lung cancer; TPS, Tumor Proportion Score.